Zotarolimus Background


The inherent advance inhibitory backdrop of abounding anti-cancer agents accomplish these drugs ideal candidates for the blockage of restenosis. However, these aforementioned backdrop are generally associated with cytotoxicity at doses which block corpuscle proliferation. Therefore, the different cytostatic attributes of the immunosuppressant rapamycin was the base for the development of zotarolimus by Johnson and Johnson.
Rapamycin was originally accustomed for the blockage of renal displace bounce in 1999. More recently, Abbott Laboratories developed a admixture from the aforementioned class, zotarolimus, as the aboriginal cytostatic abettor to be used alone for supply from drug-eluting stents to anticipate restenosis.